Literature DB >> 15595835

Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Carol B Fowler1, Irina D Pogozheva, Andrei L Lomize, Harry LeVine, Henry I Mosberg.   

Abstract

Site-directed mutagenesis and design of Zn(2+)-binding centers have been used to determine a set of specific tertiary interactions between the mu-opioid receptor, a rhodopsin-like G protein-coupled receptor (GPCR), and its cyclic peptide agonist ligand, Tyr(1)-c(S-Et-S)[d-Cys(2)-Phe(3)-d-Pen(4)]NH(2) (JOM6). The binding affinity of the tetrapeptide is strongly dependent on the nature of its first and third residues and on substitutions at positions 213, 216, 237, 300, 315, and 318 of the mu-opioid receptor. His(1) and His(3) analogues of the ligand were able to form metal-binding complexes with the V300C and G213C/T315C receptor mutants, respectively. Direct contact of the Phe(3) residue of JOM6 with Gly(213), Asp(216), Thr(315), and Trp(318) of the receptor was suggested by the binding affinities of His(3)-, Nle(3)-, Leu(3)-, Aci(3)-, Delta(E)Phe(3)-, and Delta(Z)Phe(3)-substituted peptides with the G213C/T315C, D216V, T315C, and W318L mutants. The improved binding affinity of the free carboxylate analogue of JOM6 for binding to the E229D mutant revealed an interaction between the C-terminal group of the peptide and Glu(229) of the receptor. The experimental constraints that were obtained were applied for distance geometry modeling of the mu-receptor in complex with the tetrapeptide agonist ligand, JOM6. The active conformation of the opioid receptor was calculated using the crystal structure of "inactive" rhodopsin and published engineered and intrinsic metal-binding sites and disulfide bonds that allow or facilitate activation of GPCRs. Interhelical H-bonds existing in the mu-receptor were applied as additional distance constraints. The calculated model of the receptor-ligand complex can serve as a prototype of the active state for all rhodopsin-like GPCRs. It displays a strongly shifted transmembrane helix 6 (TM6) and reorientation of the conserved Trp(293) residue in TM6 upon its interaction with the agonist. Importantly, the binding pockets of the active and inactive states are not identical, which implies distinct interaction modes of agonists and antagonists. In the active state, the binding pocket of the mu-receptor is complementary to the previously proposed receptor-bound conformation of JOM6.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15595835     DOI: 10.1021/bi048413q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists.

Authors:  Irina D Pogozheva; Biao-Xin Chai; Andrei L Lomize; Tung M Fong; David H Weinberg; Ravi P Nargund; Michael W Mulholland; Ira Gantz; Henry I Mosberg
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

Review 3.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  "Carba"-analogues of fentanyl are opioid receptor agonists.

Authors:  Grazyna Weltrowska; Nga N Chung; Carole Lemieux; Jianxin Guo; Yixin Lu; Brian C Wilkes; Peter W Schiller
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

5.  Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.

Authors:  Jessica P Anand; Vanessa R Porter-Barrus; Helen V Waldschmidt; Larisa Yeomans; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Biopolymers       Date:  2014-01       Impact factor: 2.505

6.  Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.

Authors:  Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

7.  A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism.

Authors:  Pavel Gris; Josee Gauthier; Philip Cheng; Dustin G Gibson; Denis Gris; Oskar Laur; John Pierson; Sean Wentworth; Andrea G Nackley; William Maixner; Luda Diatchenko
Journal:  Mol Pain       Date:  2010-06-02       Impact factor: 3.395

8.  Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.

Authors:  Jessica P Anand; Lauren C Purington; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  Chem Biol Drug Des       Date:  2012-09-12       Impact factor: 2.817

9.  The full-length mu-opioid receptor: a conformational study by circular dichroism in trifluoroethanol and membrane-mimetic environments.

Authors:  Isabelle Muller; Valérie Sarramégna; Marie Renault; Vincent Lafaquière; Sarra Sebai; Alain Milon; Franck Talmont
Journal:  J Membr Biol       Date:  2008-06-24       Impact factor: 1.843

10.  Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.

Authors:  Aubrie A Harland; Aaron M Bender; Nicholas W Griggs; Chao Gao; Jessica P Anand; Irina D Pogozheva; John R Traynor; Emily M Jutkiewicz; Henry I Mosberg
Journal:  J Med Chem       Date:  2016-05-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.